Giuseppe Faggian

Prof. Giuseppe Faggian

Giuseppe Faggian
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMarinos Kallikourdis
Marinos Kallikourdis
EMElisa Martini
Elisa Martini
PCPierluigi Carullo
Pierluigi Carullo
CSClaudia Sardi
Claudia Sardi
GRGiuliana Roselli
Giuliana Roselli
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
Heart failure (HF) is a leading cause of mortality. Inflammation is implicated in HF, yet clinical trials targeting pro-inflammatory cytokines in HF were unsuccessful, possibly due to redundant functions of individual cytokines. Searching for better cardiac inflammation targets, here we link T cells with HF development in a mouse model of pathological cardiac hypertrophy and in human HF patients. T cell costimulation blockade, through FDA-approved rheumatoid arthritis drug abatacept, leads to highly significant delay in progression and decreased severity of cardiac dysfunction in the mouse HF model. The therapeutic effect occurs via inhibition of activation and cardiac infiltration of T cells and macrophages, leading to reduced cardiomyocyte death. Abatacept treatment also induces production of anti-inflammatory cytokine interleukin-10 (IL-10). IL-10-deficient mice are refractive to treatment, while protection could be rescued by transfer of IL-10-sufficient B cells. These results suggest that T cell costimulation blockade might be therapeutically exploited to treat HF.

1 October 2012 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AMAldo Domenico Milano
Aldo Domenico Milano
GFGiuseppe Faggian
Giuseppe Faggian
MDMikhail Dodonov
Mikhail Dodonov
GGGiorgio Golia
Giorgio Golia
ATAnna Tomezzoli
Anna Tomezzoli
AMAlessandro Mazzucco
Alessandro Mazzucco

30 June 2015 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
Fausto BiancariFausto Biancari
Fausto Biancari
VRVito G Ruggieri
Vito G Ruggieri
APAndrea Perrotti
Andrea Perrotti
PSPeter Svenarud
Peter Svenarud
MDMagnus Dalén
Magnus Dalén
TJTatu Juvonen
Tatu Juvonen
Clinical evidence in coronary surgery is usually derived from retrospective, single institutional series. This may introduce significant biases in the analysis of critical issues in the treatment of these patients. In order to avoid such methodological limitations, we planned a European multicenter, prospective study on coronary artery bypass grafting, the E-CABG registry. The E-CABG registry is a multicenter study and its data are prospectively collected from 13 centers of cardiac surgery in university and community hospitals located in six European countries (England, Italy, Finland, France, Germany, Sweden). Data on major and minor immediate postoperative adverse events will be collected. Data on late all-cause mortality, stroke, myocardial infarction and repeat revascularization will be collected during a 10-year follow-up period. These investigators provided a score from 0 to 10 for any major postoperative adverse events and their rounded medians were used to stratify the severity of these complications in four grades. The sum of these scores for each complication/intervention occurring after coronary artery bypass grafting will be used as an additive score for further stratification of the prognostic importance of these events. The E-CABG registry is expected to provide valuable data for identification of risk factors and treatment strategies associated with suboptimal outcome. These information may improve the safety and durability of coronary artery bypass grafting. The proposed classification of postoperative complications may become a valuable research tool to stratify the impact of such complications on the outcome of these patients and evaluate the burden of resources needed for their treatment. NCT02319083

6 March 2013 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
RRRoberta Roncarati
Roberta Roncarati
CAChiara Viviani Anselmi
Chiara Viviani Anselmi
PKPeter Krawitz
Peter Krawitz
Giovanna LattanziGiovanna Lattanzi
Giovanna Lattanzi
YKYskert von Kodolitsch
Yskert von Kodolitsch
PRPeter N. Robinson
Peter N. Robinson

1 December 2015 in Circulation
Verified
Journal Article
Open access
AGAlexey V. Glukhov
Alexey V. Glukhov
MBMarina Balycheva
Marina Balycheva
JSJose Luis Sanchez-Alonso
Jose Luis Sanchez-Alonso
ZIZeki Ilkan
Zeki Ilkan
AAAnita Alvarez-Laviada
Anita Alvarez-Laviada
JGJulia Gorelik
Julia Gorelik
Background—: Distinct subpopulations of L-type calcium channels (LTCCs) with different functional properties exist in cardiomyocytes. Disruption of cellular structure may affect LTCC in a microdomain-specific manner and contribute to the pathophysiology of cardiac diseases, especially in cells lacking organized transverse tubules (T-tubules) such as atrial myocytes (AMs). Methods and Results—: Isolated rat and human AMs were characterized by scanning ion conductance, confocal, and electron microscopy. Half of AMs possessed T-tubules and structured topography, proportional to cell width. A bigger proportion of myocytes in the left atrium had organized T-tubules and topography than in the right atrium. Super-resolution scanning patch clamp showed that LTCCs distribute equally in T-tubules and crest areas of the sarcolemma, whereas, in ventricular myocytes, LTCCs primarily cluster in T-tubules. Rat, but not human, T-tubule LTCCs had open probability similar to crest LTCCs, but exhibited ≈40% greater current. Optical mapping of Ca 2+ transients revealed that rat AMs presented ≈3-fold as many spontaneous Ca 2+ release events as ventricular myocytes. Occurrence of crest LTCCs and spontaneous Ca 2+ transients were eliminated by either a caveolae-targeted LTCC antagonist or disrupting caveolae with methyl-β-cyclodextrin, with an associated ≈30% whole-cell I Ca,L reduction. Heart failure (16 weeks post–myocardial infarction) in rats resulted in a T-tubule degradation (by ≈40%) and significant elevation of spontaneous Ca 2+ release events. Although heart failure did not affect LTCC occurrence, it led to ≈25% decrease in T-tubule LTCC amplitude. Conclusions—: We provide the first direct evidence for the existence of 2 distinct subpopulations of functional LTCCs in rat and human AMs, with their biophysical properties modulated in heart failure in a microdomain-specific manner.

9 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TZTania Zaglia
Tania Zaglia
PCPaola Ceriotti
Paola Ceriotti
ACAntonio Campo
Antonio Campo
GBGiulia Borile
Giulia Borile
AAAndrea Armani
Andrea Armani
Marco MongilloMarco Mongillo
Marco Mongillo
Significance: Mitochondrial calcium uniporter (MCU) is the core channel subunit of the mitochondrial Ca 2+ uniporter complex (MCUC) and contributes to the regulation of ATP production. Here, we identify that the adaptive and maladaptive remodeling occurring in rodent and human cardiomyocytes is associated with changes in MCU content, which are inversely correlated with those of its regulator microRNA-1 (miR-1). The present study thus defines the molecular mechanism by which MCU content and, consequently, mitochondrial Ca 2+ uptake are directly modified by alteration of miR-1, a key regulator affecting physiological and pathological heart growth. These findings provide evidence for the miR-1/MCU axis as a potential target for the development of novel therapeutic approaches.